c-erbB-2 expression in different histological types of invasive breast carcinoma.

Soomro, S; Shousha, Sami; Taylor, P; Shepard, H M; Feldmann, Marc

doi:10.1136/jcp.44.3.211

Cited by 69 publications

(32 citation statements)

References 30 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…36 In the present study, CerbB2 positivity was seen in almost 45% of ER-negative cases, although the overall expression is around 30% in the entire ER-positive and -negative series and in series reported by others. [37][38][39] Similarly, a higher percentage of ER-negative tumors in the present study also showed aberrant expression of p53 (60%). A strong association between specific mutations and short survival and poor response to treatment has been reported; a meta-analysis study of somatic mutations of p53 in breast cancers reported overall relative hazards for recurrence and death at 1.5 and 2.0, respectively.…”

Section: Estrogen Receptor-negative Breast Carcinomassupporting

confidence: 52%

Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis

et al. 2005

View full text Add to dashboard Cite

Estrogen receptor (ER)-negative breast cancers are a group of tumors with poor prognosis and fewer cancer prevention and treatment strategies compared to ER-positive tumors. The aim of this study was to assess the morphological characteristics and immunohistochemical profile of ER-negative tumors and thus to understand the biological behavior and unique nature. In total, 291 consecutive ER-negative cases available from our primary breast cancer series were examined. Hematoxylin-and eosin-stained sections of all the cases were studied for several morphological parameters and their immunophenotype profile. These findings were correlated with patient and tumor characteristics and survival data. ER-negative tumors constituted 30% of the primary operable breast cancer series. The majority of tumors were grade 3 (94%) and the commonest histological types were ductal/no specific type (85%), and atypical medullary carcinoma (8%). High-grade comedo-type necrosis, lymphoid stroma, central necrosis/fibrosis and pushing margins were the most common morphological features. The presence of a pushing margin showed a significant relation to androgen receptor negativity, absence of epidermal growth factor receptor expression and negative lymph nodes. Lymphoid stroma and comedo-necrosis correlated with higher tumor grade. ER-negative breast cancers are a distinct group of tumors with several common morphological features. Grade 3 histology, pushing margin, lymphoid stroma, comedo-type necrosis and central fibrosis/necrosis are the dominant morphological findings. The presence of a pushing margin appears to have a significant correlation with negative lymph node status. ER-negative tumors show a higher expression of p53, CerbB2 and epidermal growth factor receptor compared to ER-positive breast cancer. These unique features support the concept that ER-negative tumors are a morphologically and phenotypically distinct entity and provide a rationale for the study and use of newer promising agents in the treatment of ER-negative breast cancer.

show abstract

Section: Estrogen Receptor-negative Breast Carcinomassupporting

confidence: 52%

Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Sections were incubated overnight at 4'C with mAbl, at a concentration of 2.5fLgml-'. For negative controls the primary antibody was omitted (Barnes et al, 1988;Lovekin et al, 1989 (Figures 1 and 2) -as suggested by Soomro et al (1991). Grade attribution was blind of patient's status and previously assessed nuclear grade.…”

mentioning

confidence: 99%

Prognostic significance of c-erbB-2 expression in node negative breast cancer

Bianchi¹,

Paglierani²,

Zampi³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

Summary The prognostic value of c-erbB-2 oncogene expression was studied retrospectively in a consecutive series of 230 node negative breast cancers, followed-up for at least 7 years after primary treatment. The expression of c-erbB-2 oncoprotein was determined on formalin-fixed paraffin-embedded tissue, using a monoclonal anti-c-erbB-2 antibody by the avidin-biotin immunoperoxidase method. Positive immunostaining was observed in 20.9% of cases, whereas strong diffuse positivity was recorded only in 8.7% of cases. C-erbB-2 gene product showed no association to T category or nuclear grade. A significant association of c-erbB-2 expression to prognosis was observed only for cases showing a strong diffuse immunostaining, but such an association was no longer statistically significant at multivariate analysis adjusting for other prognostic factors such as T category and nuclear grading. C-erbB-2 expression is of no value to predict the clinical course of node negative patients in the current practice.

show abstract

“…Средний возраст больных -53-58 лет [20]. Рецепторы эстрогена и проге-стерона обычно положительны (ER >100% и PgR ~69%), HER2 и EGFR-негативны [21]. Пятилетняя и 10-летняя выживаемость составляет порядка 100% при чистой кри-брозной карциноме (90% опухоли представлено криброз-ными структурами) и уменьшается по мере нарастания протокового компонента [22].…”

Section: криброзный рмжunclassified